Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
$5.50
$5.76(73.00%)
At close: 4:00 PM EST
$5.50
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.47M
Market Cap
$763.80M
Enterprise Value$384.74M
Total Cash (Recent Filing)$506.51M
Total Debt (Recent Filing)$100.17M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 19, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding139,125,030
10 Day Avg. Volume1,351,063
30 Day Avg. Volume1,474,389
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.87
Price to Sales (P/S)13.48
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue22.82
Enterprise Value/Gross Profit-0.88
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$17.67Price Target Upside221.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressVir announced complete enrollment in ECLIPSE 1, the first registrational Phase 3 trial in HDV, approximately two months ahead of Vir's aggressive internal assumptions, driven by continued execution, robust SOLSTICE Phase 2 data, strong investigator engagement, and the significant unmet need in HDV.
Financial StabilityCash at the end of 3Q25 of $810.7 million is expected to provide runway into mid-2027 through pivotal HDV readouts and significant progress in oncology.
Oncology Pipeline DevelopmentVIR-5500, the prostate-specific membrane antigen (PSMA)-targeted TCE, has clearance from the FDA to move into earlier-line prostate cancer in combination with androgen receptor pathway inhibitors (ARPIs).
Bears Say
Competitive Data ConcernsVIR-5500 may fail to produce competitive data.
Risk ManagementManagement emphasized that platform-wide risks must be carefully managed.
Stock PerformanceThe stock has traded down 40% year-to-date, attributed to a lack of catalyst flow and concerns on cash burn.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.16 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $763.80M.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Feb 19, 2026 which is in 91 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Nov 05, 2025. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of -$0.844 by -$0.326.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.65.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 139,125,030 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$1.17 in its last earnings report, missing expectations of -$0.844. Following the earnings report the stock price went down -5.185%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (221.27% Upside)
$17.67 (221.27% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $45.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.76%
12-Months-Change
Fundamentals
Return on Equity
-49.06%
Trailing 12-Months
Asset Growth
-31.96%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in key clinical programs and a strong financial position, with clear paths to future value creation. However, continuous financial losses and high R&D expenses remain challenges. The sentiment is balanced between the achievements and ongoing challenges.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$17.67
▲(221.27% Upside)
Technical Analysis
Ownership Overview
15.52% Insiders
15.33% Mutual Funds
26.94% Other Institutional Investors
22.61% Public Companies and
Individual Investors